Gene editing represents a groundbreaking advancement in medicine, targeting the genetic roots of diseases rather than merely alleviating symptoms. Traditional therapies often require ongoing treatment to manage conditions, whereas gene-editing techniques aim for transformative results, potentially delivering lasting health benefits through a single intervention. The CRISPR technology has ushered in a new era by enhancing the efficiency and scalability of genome modifications, transitioning gene editing from a mere research tool to a viable clinical treatment option.
The investment landscape is shifting as gene editing holds the promise of expanding therapeutic avenues for serious genetic disorders that previously lacked effective treatments. However, as an emerging technology, gene editing faces hurdles, including challenges in delivery mechanisms, long-term safety, manufacturing complexities, and regulatory pathways. The risk of unintended genetic alterations further complicates the clinical development of these therapies, underscoring both their immense potential and associated risks.
Key Players in Gene Editing
In this evolving sector, four companies stand out: CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics, and Editas Medicine. Each of these firms presents unique platforms and compelling clinical developments, providing investors with opportunities that range from established commercial successes to high-risk, high-reward projects. Notably, all four companies currently hold a Zacks Rank of #3 (Hold).
CRISPR Therapeutics: Leading the Charge
CRISPR Therapeutics is at the forefront with significant commercial validation. Its core technology, based on CRISPR/Cas9, encompasses both ex vivo (outside the body) and in vivo (inside the body) gene editing. The company’s flagship product, Casgevy, made history in 2023 as the first approved CRISPR-based ex vivo gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia. In July 2026, CRISPR Therapeutics received FDA approval to extend treatment eligibility to patients as young as two years old.
In 2023, CRISPR Therapeutics shares saw a 13.5% increase, outperforming the industry’s growth of 11.3%.
The company is also exploring next-generation technologies through its proprietary SyNTase platform and lipid nanoparticle delivery systems, aiming to broaden its gene-editing applications to include cardiovascular and rare diseases. Noteworthy candidates in development include CTX310 for cardiovascular conditions and CTX340 for refractory hypertension, both of which are currently in clinical trials.
Intellia Therapeutics: Innovative In Vivo Approaches
Intellia Therapeutics distinguishes itself with its focus on in vivo CRISPR editing. Rather than extracting cells for external editing, Intellia employs lipid nanoparticles to deliver gene-editing payloads directly to target tissues. The company has achieved the significant milestone of advancing in vivo genome-editing candidates into phase III clinical trials.
Year to date, Intellia’s shares have surged by 42.8%, significantly outpacing the industry growth.
Among its lead candidates, lonvoguran ziclumeran (lonvo-z) has shown impressive results in clinical trials for hereditary angioedema, demonstrating an 87% reduction in attack frequency compared to placebo. A rolling biologics license application was initiated in April 2026, with expectations for FDA acceptance by the end of the year. If approved, lonvo-z is poised for a potential U.S. launch in early 2027.
Beam Therapeutics: Precision Through Base Editing
Beam Therapeutics introduces a novel approach with its base editing technology, which allows for precise single-base modifications without the double-strand breaks common in traditional CRISPR/Cas9 methods. This technique, combined with lipid nanoparticle delivery and ex vivo editing, aims to develop durable genetic therapies targeting various hematological and rare diseases.
Beam Therapeutics has experienced a 7.4% gain in shares year to date, although this growth lags behind industry averages.
The company’s lead candidate, risto-cel, is an ex vivo base-edited therapy for sickle cell disease, currently in the phase I/II BEACON study. Plans are in place to submit a biologics license application by the end of 2026. Additionally, Beam is advancing BEAM-302 for alpha-1 antitrypsin deficiency and expanding its portfolio with candidates targeting other genetic disorders, reinforcing the viability of its base-editing platform across diverse applications.
Editas Medicine: Focused on In Vivo Gene Editing
Editas Medicine has strategically pivoted towards in vivo CRISPR-based gene editing, developing therapies that aim to directly enhance normal gene expression. Their approach includes targeted lipid nanoparticle delivery to tissues such as the liver, opening the door to a wider array of treatable conditions.
In 2023, Editas shares rose by 34.1%, significantly outperforming the industry’s 2.5% growth.
The flagship asset, EDIT-401, is an investigational therapy designed to significantly lower LDL cholesterol levels through upregulation of the LDL receptor gene, targeting heterozygous familial hypercholesterolemia. Progress is being made toward a phase I/II study in Australia and New Zealand, with promising preclinical results supporting its potential effectiveness.
Risk and Speculation
Among the four companies, Editas Medicine carries the highest speculative risk. While CRISPR has an approved product, and Intellia’s candidates are in advanced stages, Beam’s diverse pipeline offers a balance of early-stage opportunities. Editas has concentrated its efforts solely on in vivo approaches after discontinuing its ex vivo programs, presenting both execution risk and a focused investment proposition.
Conclusion
The gene-editing landscape is rapidly evolving with immense potential for transformative therapies. Companies like CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics, and Editas Medicine are leading the charge, each with unique technologies and clinical strategies. As this sector matures, it offers exciting opportunities for investors willing to navigate the associated risks and rewards.
- Takeaway Points:
- Gene editing targets diseases at their genetic source for potentially permanent solutions.
- CRISPR Therapeutics leads with commercial validation and diverse pipeline opportunities.
- Intellia focuses on innovative in vivo editing, showcasing promising trial results.
- Beam’s base editing technology offers precision without damaging DNA.
- Editas is concentrating on in vivo applications, with a high-risk, high-reward profile.
Read more → www.theglobeandmail.com